Skip to main content
Equibles
DFTX logo

DFTX · Definium Therapeutics, Inc.

Track DFTX — free

Use DFTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DFTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$44.91 -0.49 (-1.08%) At close · Aug 21
Market Cap
$6.10B
Shares
134.37M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$44.91 Open$45.89 Day$44.81–46.57 52W close$8.88–48.45 Avg vol 30d2.0M Short int10.7M · 8.0% float · 6.6d Short vol54% Last earningsAug 6, 2026 DataAug 2022–Aug 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Aug 29, 2022; bars on opposite sides are not compared.

Up next

Next earnings call
Nov 9, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High
      Market backdrop VIX 15.1 · calm Equity put/call 0.51
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +91%
      above
      Price vs 50-day avg +8%
      above
      RSI (14) 54
      neutral
      MACD trend Negative
      52-week position 91%
      near high
      Momentum
      relative strength
      Very Strong
      1-month return +4%
      trailing
      6-month return +161%
      trailing
      YTD return +235%
      this year
      Relative strength +150%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $42 › 200d $23 — 50d above 200d
      Institutional flow Accumulating
      +46% holders QoQ · +151 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      7.99% of float · ▲ +0.9% MoM · 6.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      366 holders — 13F breadth
      Squeeze score 77
      high risk · 0–100
      Fundamentals
      Fair
      EPS growth −34%
      Y/Y
      Balance sheet $217.3M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 80%
      annualized · 1-yr
      Max drawdown −25%
      past year
      ATR 6.2%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 2 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +91% Bullish
      Price vs 50-day avg
      +8% Bullish
      RSI (14)
      54 Neutral
      MACD trend
      Negative Bearish
      52-week position
      91% Bullish
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $42 › 200d $23 — 50d above 200d
      Institutional flow Accumulating
      +46% holders QoQ · +151 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      7.99% of float · ▲ +0.9% MoM · 6.6 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      366 holders — 13F breadth
      Price context
      position in its 52-week range
      Range low $9 Now $45 · 91% Range high $48
      vs 200-day avg +91% vs 50-day avg +8%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      cash, cash equivalents and investments $412M as of December 31, 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      DFTX
      Definium Therapeutics, Inc.
      this stock
      		$6.10B +235.4% — — 8.0%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.91B +20.9% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $85.87B +8.1% +20.8% 20.7 3.3%
      ARGX
      Argenx SE
      		 $64.56B +23.6% — — 2.1%
      CSLLY
      Csl Ltd
      		 $58.31B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      366
      % held
      88.9%
      Net QoQ
      +39.6M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      176
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      10.7M
      Days to cover
      6.6d
      Change
      +97.4K sh
      View
      Short Volume
      Short vol %
      54%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      186
      Value
      $7.8K
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      47.3%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Net income (FY)
      $-183.8M
      EPS diluted
      $-2.06
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 12, 2026
      This year
      16
      View
      Proposed Sales
      Value
      $120.8K
      Shares
      2.9K
      Filed
      Jun 25, 2026
      View
      Exempt Offerings
      Offering
      $7.0M
      Filed
      May 5, 2025
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 6, 2026
      View

      Performance

      Raw-price comparisons begin at the captured split on Aug 29, 2022; windows that need an earlier baseline remain unavailable.

      5D 20D 120D MTD YTD
      DFTX +5.4% +4.0% +161.4% +3.2% +235.4%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY +6.7% +0.4% +149.9% +0.7% +223.1%
      Key facts CIK 1813814 CUSIP 24477V105 13F (30d) 340 filings 336 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)